Video index

1. Call to order

2. Consideration of October 21, 2022, draft meeting minutes

3. HHS Ethics Policy overview

4. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL)

5. Public comment on single new drugs to be reviewed for the Medicaid PDL

6. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration

7. Executive work session

8. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration

9. Retrospective drug utilization review (DUR): Conduent, LLC

10. Prospective prior authorization proposals (clinical edits): Kepro, LLC

11. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy

12. Review of action items for next meeting: Apr 21, 2023, 9:00 a.m.

Jan 20, 2023 Drug Utilization Review Board (DURB) Agenda

Full agenda
Share this video

1. Call to order

2. Consideration of October 21, 2022, draft meeting minutes

3. HHS Ethics Policy overview

4. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL)

5. Public comment on single new drugs to be reviewed for the Medicaid PDL

6. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration

7. Executive work session

8. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration

9. Retrospective drug utilization review (DUR): Conduent, LLC

10. Prospective prior authorization proposals (clinical edits): Kepro, LLC

11. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy

12. Review of action items for next meeting: Apr 21, 2023, 9:00 a.m.

© 2003-2024 Swagit Productions, LLC